ReviewJournal of ophthalmology2021
Intravitreal Therapy for Diabetic Macular Edema: An Update.
Review in Journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics.Scientific reports · 2025Trial
- Immediate versus delayed dexamethasone implantation during vitrectomy for diabetic macular edema with secondary epiretinal membrane: A retrospective comparative study.The Journal of international medical research · 2026Article
- A Field-Based Cost-Effectiveness Study of Aflibercept and Bevacizumab in Treat-and-Extend Versus Pro Re Nata Protocols for Diabetic Macular Edema in Iraq.Clinical drug investigation · 2026Article
- Efficacy of Avastin in Improving Visual Acuity and Reducing Retinal Swelling in Patients with Diabetic Retinopathy at a Hospital in Gauteng (SA).Clinical optometry · 2026Article
- Nonadherence to anti-VEGF intravitreal injections in patients with diabetic macular edema : The names of the authors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- The Causal Relationship and Association between Biomarkers, Dietary Intake, and Diabetic Retinopathy: Insights from Mendelian Randomization and Cross-Sectional Study.Diabetes & metabolism journal · 2025Article
- Safety of an Intravitreal Bevacizumab Biosimilar (MVASI).Clinical & experimental ophthalmology · 2025Article
- Predictors of Peripheral Retinal Non-Perfusion in Clinically Significant Diabetic Macular Edema.Journal of clinical medicine · 2024Article
- Oxidative Stress and Inflammation-Related mRNAs Are Elevated in Serum of a Finnish Wet AMD Cohort.Investigative ophthalmology & visual science · 2024Article
- Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema.Eye (London, England) · 2024Article
- Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies.Cureus · 2024Review
- Retrospective Study of Diabetic Retinopathy and Macular Edema in Southern Part of Bangladesh.Journal of ophthalmology · 2024Article
- Review
- Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.The Journal of pharmacology and experimental therapeutics · 2023Review
- Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema.Scientific reports · 2023Article
- Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them.International journal of molecular sciences · 2023Review
- Ocular Delivery of Therapeutic Proteins: A Review.Pharmaceutics · 2023Review
- Characteristics and Treatment Patterns of Patients with Diabetic Macular Edema Non-Responsive to Anti-Vascular Endothelial Growth Factor Treatment in Ontario, Canada.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Potential disease biomarkers for diabetic retinopathy identified through Mendelian randomization analysis.Frontiers in endocrinology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight-threatening condition, it is also among the most accessible to treatment. Many different treatment options including photocoagulation, intravitreal medical treatment (either vascular endothelial growth factor inhibitors or corticosteroids therapies), and surgical removal are currently available. Although laser has been considered as the gold standard for many years, over the past several years vascular endothelial growth factor inhibitors (anti-VEGFs) have become first-line therapy. However, many patients do not adequately respond to them. With the development of sustained-release corticosteroid devices, steroids have gained a presence in the management of the DME. We review and update the role of anti-VEGF and intravitreal sustained-release corticosteroid management of DME. According to the currently available scientific evidence, the choice of one anti-VEGF over another critically depends on the baseline best-corrected visual acuity (BCVA). While aflibercept may be the drug of choice in low baseline BCVA, the three anti-VEGFs (bevacizumab, ranibizumab, and aflibercept) provided similar functional outcomes when the baseline BCVA was higher. DEX implants are a valuable option for treating DME, although they are usually seen as a second choice, particularly in those eyes that have an insufficient response to anti-VEGF. The new evidence suggested that, in eyes that did not adequately respond to anti-VEGF, switching to a DEX implant at the time to 3 monthly anti-VEGF injections provided better functional outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.